An overview of pazopanib in metastatic renal cell carcinoma (mRCC) in Ministry of Health (MOH), Malaysia: A multicentre experience

被引：0
|
作者：
Malwinder, S. [1 ]
Nurazzahra, K. [2 ]
Sandya, S. [2 ]
Chen, M. [1 ]
机构：
[1] Hosp Sultan Ismail, Dept Radiotherapy & Oncol, Johor Baharu, Malaysia
[2] Hosp Kuala Lumpur, Dept Radiotherapy & Oncol, Kuala Lumpur, Malaysia
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
277P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC).
    Ghatalia, Pooja
    Handorf, Elizabeth A.
    Deng, Mengying
    Zibelman, Matthew R.
    Abbosh, Philip
    Anari, Fern
    Greenberg, Richard E.
    Viterbo, Rosalia
    Chen, David
    Smaldone, Marc C.
    Kutikov, Alexander
    Geynisman, Daniel M.
    Uzzo, Robert Guy
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] Outcomes of "real world" treatment for metastatic renal cell carcinoma (mRCC).
    Harrison, Michael Roger
    George, Daniel J.
    Walker, Mark S.
    Hudson, Lori L.
    Chen, Connie
    Korytowsky, Beata
    Stepanski, Edward J.
    Abernethy, Amy P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [43] PATTERNS OF CARE IN AUSTRALIAN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
    Dai, D.
    Kanjanapan, Y.
    Kwan, E.
    Yip, D.
    Lawrentschuk, N.
    Andrews, M.
    Davis, I. D.
    Azad, A.
    Rosenthal, M.
    Wong, S.
    Arifeen, S.
    Alam, M.
    Gibbs, P.
    Tran, B.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 33 - 33
  • [44] Ixabepilone (BMS-247550) and metastatic renal cell carcinoma (mRCC)
    Huang, H.
    Menefee, M. E.
    Edgerly, M.
    Kotz, H.
    Poruchynsky, M.
    Stein, W. D.
    Bates, S. E.
    Fojo, A. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [45] Stereotactic Radiation Therapy (SRT) for Metastatic Renal Cell Carcinoma (mRCC)
    Meyer, E.
    Pasquier, D.
    Bernadou, G.
    Calais, G.
    Carrie, C.
    Stefan, D.
    Theodore, C.
    Albiges, L.
    Bossi, A.
    Maroun, P.
    De Crevoisier, R.
    Hennequin, C.
    Lagrange, J. L.
    Lesaunier, F.
    Grellard, J. M.
    Clarisse, B.
    Habrand, J. L.
    Dugue, A. E.
    Joly, F.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E247 - E248
  • [46] Sunitinib safety and tolerability in patients with metastatic renal cell carcinoma (MRCC)
    Ferrari, A.
    Sabbatini, R.
    Maur, M.
    Giovannelli, S.
    Jovic, G.
    Conte, P.
    ANNALS OF ONCOLOGY, 2006, 17 : XI83 - XI83
  • [47] Current treatment options for recurrent/metastatic renal cell carcinoma (mRCC)
    Virchow, Isabel
    Grunwald, Viktor
    AKTUELLE UROLOGIE, 2021, 52 (05) : 439 - 444
  • [48] PATTERNS OF CARE IN AUSTRALIAN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (mRCC)
    Dai, D.
    Kanjanapan, Y.
    Kwan, E.
    Yip, D.
    Lawrentschuk, N.
    Andrews, M.
    Davis, I. D.
    Azad, A.
    Rosenthal, M.
    Wong, S.
    Arifeen, S.
    Alam, M.
    Gibbs, P.
    Tran, B.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 54 - 54
  • [49] Prospective translational study investigating circulating predictors of outcome to first-line pazopanib in patients with metastatic renal cell carcinoma (mRCC)
    Grassi, P.
    Verzoni, E.
    Ratta, R.
    Martinetti, A.
    Montone, R.
    Tagliabue, E.
    de Braud, F.
    Procopio, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [50] A phase II study of patients with advanced or metastatic renal cell carcinoma (mRCC) receiving pazopanib after previous checkpoint inhibitor treatment
    Powles, T. B.
    Oudard, S.
    Grunwald, V.
    Calvo, E.
    Michaelson, M. D.
    Burotto, M.
    Melichar, B.
    Tyagi, R.
    Hilmi, F.
    Gaur, A.
    Hirschberg, Y.
    Heng, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S564 - S564
12345